XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Debt Obligations - 2027 Term Loan - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 07, 2019
USD ($)
Mar. 31, 2022
USD ($)
Jan. 31, 2022
USD ($)
item
Jun. 30, 2023
USD ($)
Mar. 31, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Sep. 14, 2022
USD ($)
Jan. 05, 2022
USD ($)
tranche
Apr. 30, 2020
USD ($)
Feb. 29, 2016
USD ($)
Debt Instrument [Line Items]                      
Outstanding amount paid off             $ 81,750        
Outstanding amount payoff             $ 109,000        
2027 Term Loans                      
Debt Instrument [Line Items]                      
Interest rate       13.40%              
2027 Term Loans | BioPharma Credit Investments V GP LLC                      
Debt Instrument [Line Items]                      
Principal amount                 $ 300,000    
Number of tranches | tranche                 4    
Net carrying value       $ 245,963   $ 245,963          
Quarterly payments | item     5                
Loan agreement covenants, minimum trailing twelve month net sales for current quarter     $ 200,000     200,000          
Loan agreement covenants, minimum trailing twelve month net sales for the quarter ended March 30, 2024     210,000                
Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended June 30, 2024     230,000                
Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended September 30, 2024     270,000                
Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended December 31, 2024 and thereafter     $ 300,000                
Mandatory prepayment term     10 days                
Debt discounts and issuance costs     $ 6,800                
Remaining unamortized debt discount and debt offering costs       $ 4,037   $ 4,037          
Interest rate       13.40%              
2027 Term Loans | Additional facility amount | BioPharma Credit Investments V GP LLC                      
Debt Instrument [Line Items]                      
Principal amount     $ 100,000                
2027 Term Loans | Through March 31, 2023 | BioPharma Credit Investments V GP LLC                      
Debt Instrument [Line Items]                      
Stated interest rate     8.25%                
2027 Term Loans | Through March 31, 2023 | BioPharma Credit Investments V GP LLC | LIBOR                      
Debt Instrument [Line Items]                      
Floor On Variable Rate     1.00%                
2027 Term Loans | Starting April 1, 2023 | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]                      
Debt Instrument [Line Items]                      
Amount added to the variable component           0.26161%          
Floor On Variable Rate           1.00%          
2027 Term Loans | Starting April 1, 2023 | BioPharma Credit Investments V GP LLC                      
Debt Instrument [Line Items]                      
Stated interest rate       8.25%   8.25%          
Tranche A Loan, funded January 5, 2022 | BioPharma Credit Investments V GP LLC                      
Debt Instrument [Line Items]                      
Principal amount                 $ 100,000    
Debt discounts and issuance costs     $ 7,800                
Tranche B Loan, funded on March 31, 2022 | BioPharma Credit Investments V GP LLC                      
Debt Instrument [Line Items]                      
Principal amount   $ 100,000     $ 100,000            
Debt discounts and issuance costs         2,300            
Convertible notes, Issuance Cost   $ 1,000     $ 1,000            
Tranche C Loan, not funded between April 1, 2022 and March 17, 2023 | BioPharma Credit Investments V GP LLC                      
Debt Instrument [Line Items]                      
Principal amount     50,000                
Tranche D Loan, funded on September 14, 2022 | BioPharma Credit Investments V GP LLC                      
Debt Instrument [Line Items]                      
Principal amount               $ 50,000      
Convertible notes, Issuance Cost               $ 500      
1.5% Convertible Senior Subordinated Notes due 2026 | Convertible Notes                      
Debt Instrument [Line Items]                      
Principal amount                   $ 230,000  
Net carrying value       $ 226,228   $ 226,228          
Stated interest rate                   1.50%  
Remaining unamortized debt discount and debt offering costs       $ 3,772   $ 3,772          
Effective interest rate       2.10%   2.10%          
1.5% Convertible Senior Subordinated Notes due 2026 | BioPharma Credit Investments V GP LLC | Scenario, Plan | Minimum                      
Debt Instrument [Line Items]                      
Principal amount     50,000                
8.2% Convertible Notes due 2022 | Convertible Notes                      
Debt Instrument [Line Items]                      
Principal amount     100,000               $ 100,000
Stated interest rate   8.20%     8.20%           8.20%
Outstanding amount payoff   $ 111,100 111,100                
2025 Term Loan | Lender                      
Debt Instrument [Line Items]                      
Principal amount $ 75,000   75,000                
Outstanding amount paid off     $ 81,900                
Total term of the loan 6 years                    
Tranches A, B and D | BioPharma Credit Investments V GP LLC                      
Debt Instrument [Line Items]                      
Remaining unamortized debt discount and debt offering costs       $ 4,000   $ 4,000          
Remaining term           3 years 6 months